PROVECTUS BIOPHARMS - PVCT STOCK NEWS

Provectus (OTCQB: PVCT) announced the publication of preclinical research on its pharmaceutical-grade rose bengal, demonstrating its effectiveness against Gram-positive bacteria, including drug-resistant strains. The study, led by Dr. Michio Kurosu from the University of Tennessee Health Science Center, highlights that Provectus' formulation kills bacteria rapidly, eradicates biofilms, and shows low resistance development. The results support the potential of rose bengal as an anti-infective drug for skin and soft tissue infections, advancing its clinical application.

Provectus has revealed promising results from a meta-analysis of its Phase 2 and 3 clinical trials involving PV-10 for treating Stage III cutaneous melanoma. The analysis included 184 patients, boasting a median overall survival of 44.9 months. PV-10 demonstrated a 56% complete response rate across 774 injected lesions. Data from the expanded access program showed a rapid treatment response with favorable safety profiles. This substantial data set spans 12 years and over 1,200 lesions, indicating the drug’s effectiveness against locoregional melanoma, positioning it favorably against standard therapies.

Provectus announced updated results from its Phase 1b clinical trial of the cancer immunotherapy PV-10, in combination with Keytruda, for advanced cutaneous melanoma refractory to immune checkpoint blockade.

Key findings include a median overall survival of 34.1 months and a median progression-free survival of 4.9 months. The study reported a 5% complete response, a 26% objective response rate, and a 53% disease control rate. Treatment was mainly well-tolerated, with primarily grade 1-2 injection site reactions.

Provectus (OTCQB: PVCT) has updated its research on the systemic administration of PV-10, an investigational immunotherapy, focusing on hematology, oncology, and virology. The Company announced new patent applications published by the USPTO, showcasing in vivo data from studies on leukemia and solid tumors that demonstrated increased survival rates in mice. Provectus plans to publish findings from these studies in peer-reviewed journals in 2022. The Company continues to seek patent protection globally and emphasizes the significance of its immune system research.

Provectus (OTCQB: PVCT) announced the presentation of data from historical clinical trials and ongoing studies of its cancer immunotherapy PV-10 at the upcoming SMR 2021 Congress, scheduled for October 28-31. The accepted abstracts will discuss PV-10's efficacy in Stage III melanoma and its combination with anti-PD-1 therapy for checkpoint-refractory patients. PV-10 has been administered to over 450 patients, showing potential for inducing immune responses against solid tumors. The company is focused on developing immunotherapy treatments for various cancers.

Provectus (OTCQB: PVCT) presented data from an ongoing clinical trial of PV-10 for treating metastatic neuroendocrine tumors at the ESMO Congress (Sept 16-21, 2021). The trial involved 12 patients, showing an objective response rate of 42% and a disease control rate of 83%. Median progression-free survival was 9.2 months, with overall survival at 22.5 months. Notable adverse effects included injection site pain in 75% of patients. The CEO expressed optimism regarding PV-10’s potential in refractory cases and future Phase 2 testing. Data collection is expected to finalize in Q4 2021.

Provectus (OTCQB: PVCT) announced the presentation of data from an ongoing clinical trial of PV-10, an investigational cancer immunotherapy for neuroendocrine tumors (NET) metastatic to the liver, at the European Society for Medical Oncology Congress from September 16-21, 2021. The abstract, titled “Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms” (#4354), highlights PV-10's potential in treating this challenging cancer type.

Provectus (PVCT) announced promising preclinical data on its investigational cancer treatment, PV-10, presented at the ASCO 2021 Annual Meeting. The study focused on oral delivery of PV-10 for adult solid tumors, demonstrating autophagic cell death across various cancer cell lines, including breast, colorectal, head and neck, and testicular cancers. Key findings revealed that testicular cancer cells showed the highest sensitivity to PV-10. The research led by Aru Narendran, MD, PhD, highlights the potential for PV-10 to selectively target certain cancers while maintaining a wide therapeutic window.

Provectus (OTCQB: PVCT) reported promising preliminary data from its Phase 1 clinical trial of PV-10 for treating neuroendocrine tumors metastatic to the liver. The findings, presented at the ASCO 2021 Annual Meeting, showed an 83% disease control rate (DCR), with a median progression-free survival (PFS) of 9.2 months and median overall survival (OS) of 22.5 months. Among the 12 heavily pre-treated patients, 42% achieved a partial response. The trial indicated a strong immune response, with mild side effects and no major safety concerns reported.